InvestorsHub Logo
Followers 11
Posts 1565
Boards Moderated 0
Alias Born 09/19/2006

Re: None

Thursday, 05/11/2017 9:13:58 AM

Thursday, May 11, 2017 9:13:58 AM

Post# of 6378
As expected no numbers in the stage II trial for AML. According to PN there has been an unprecedented enrollment in the trial by BIO-PATH standards. What does that mean? Why not just state the numbers?

"On track" to the enroll participants necessary for FDA accelerated approval by year end.

The CML safety study of 6 patients to begin in a "few" months. The safety cohort will cost $400,000 total.

IND for BP-1002 by year end.

7 million in cash left.

Iluv is correct the company will have to raise cash to stay a float this year.

All in all little was progress reported.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News